# Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study

> **NCT02195518** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 213 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT02195518
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-18
- **Primary completion:** 2018-08-14
- **Final completion:** 2018-08-14
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195518, "Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02195518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*